Chronic granulomatous disease (CGD) is a disorder of the nicotinamide adenine dinucleotide (NADPH) oxidase complex, which is a critical component of innate antimicrobial immunity [1, 2] . Two-thirds of CGD cases are a result of loss-of-function mutations in the CYBB gene on the X chromosome, which encodes the gp91 phox component of the neutrophil oxidase complex. Patients with CGD are at high risk of invasive bacterial and fungal infections and inflammatory complications [3] . Treatment of CGD traditionally has relied on prophylactic antimicrobial therapies and early aggressive treatment of infections [4] [5] [6] . Recent data on patients with CGD have indicated that despite the available therapies, longterm outcomes in these patients remain grim, particularly for those with absent or severely impaired neutrophil oxidative activity [7] . As a result, there has been great initiative to pursue definitive therapies, particularly for patients with CGD whose neutrophil oxidase activity falls into the lowest quartile. Hematopoietic stem cell transplantation (HSCT) is considered the first-line definitive therapy for patients with CGD, but limitations in national marrow-donor registries (particularly for minority patients) and the risk of graft-versus-host disease present ongoing challenges for universal curative options for these patients [1, 8, 9] . Because CGD is a disease of the hematopoietic compartment, it would seem to be an ideal setting for gene therapy to restore the faulty protein.
In addition, new targeted therapies might help to enhance residual production of reactive oxygen species (ROS) in patients with CGD.
GENE THERAPY AS A CURE FOR CGD
To date, gene therapy has relied primarily on add-back of an absent or dysfunctional protein by using a viral vector to transduce progenitor cells and restore function. Because two-thirds of CGD cases are caused by X-linked defects in the CYBB gene (X-CGD), this gene has been the main target of gene-therapy trials to date. Unlike gene-corrected lymphocytes for severe combined immunodeficiency (SCID), corrected neutrophils do not confer a survival or proliferative advantage over diseased cells [10] . Because carriers of X-CGD with skewed lyonization can themselves be symptomatic with autoimmune disease or infections, a durable minimum threshold of gene-corrected neutrophils must be achieved to alleviate the risk of infectious disease manifestations [11] . A recent single-center study of a large cohort of X-CGD carriers found that carriers in whom less than 10% of circulating neutrophils are oxidase normal are at a statistically significant increased risk for CGD-related infection, whereas those in whom ≥20% of circulating neutrophils are oxidase normal seem not to be at a statistically increased risk for infection [12] . This result suggests that achieving restoration of normal oxidase activity in 10% to 20% of circulating neutrophils would achieve significant clinical benefit with respect to infection risk, although the long-term risk of death for patients with CGD is reduced as a continuous variable at any level of increase in residual oxidase activity [7] .
EARLY GENE-THERAPY TRIALS: 1995-2010
Early trials for CGD paralleled those that targeted X-linked SCID in terms of methodologies and vectors used (Table 1) .
In 2 successive trials, Malech et al [13] used a retroviral vector to transduce autologous hematopoietic stem cells (HSCs) from patients with CGD that then were infused back into them without preconditioning. In the first trial, 5 patients with autosomal recessive CGD caused by p47 phox deficiency were given gene-corrected autologous CD34
+ stem cells at doses of 0.1 to 4.7 × 10 6 cells/kg. In these subjects, only short-term engraftment was found (mean, 0.019% oxidase-positive cells after 3-5 weeks, which were detectable for up to 6 months after infusion). In the second study, 5 patients with X-CGD received gene-corrected autologous CD34 + stem cells. Although a higher transduction rate was achieved, only low levels of gene-marked neutrophils (maximum, 0.13%) in the patients were found in the months after infusion [14, 15] . No adverse hematologic events occurred in either study, but no clear evidence of clinical benefit was found.
A subsequent trial in Germany and Switzerland used similar methods of ex vivo gene correction of CD34 + stem cells with a gammaretroviral vector containing a spleen focus-forming virus long terminal repeat (LTR) [16] . Gene therapy (GT) data presented is accurate. The gene-corrected cells unexpectedly continued to expand and reached a maximum in patient 1 of 31% of peripheral blood leukocytes and in patient 2 of 53% of peripheral blood leukocytes 1 and 13 months after infusion, respectively. However, 3 of the 4 patients developed myelodysplasia with monosomy 7 secondary to vector insertion into the MDS/EVI1 oncogene [17] . One patient died as a result of sepsis 27 months after gene therapy, whereas 2 of the patients survived subsequent HSCT [10] . These complications echoed those seen with gammaretroviral gene therapy for X-linked SCID and Wiskott-Aldrich syndrome, in which vector-related toxicity resulted in a high rate of insertional oncogenesis [18, 19] .
Subsequent trials by Kang et al [20] and Kang and Malech [21] used the same gammaretrovirus vector for the ex vivo transduction of autologous CD34 + HSCs as in their earlier trials, but conditioning with busulfan 10 mg/kg was performed for 3 patients with X-linked CGD before infusing the transduced HSCs. Two to 3 weeks after infusion, dihydrorhodamine (DHR) analysis revealed that in the 3 treated adult subjects, 26%, 5%, and 4% of peripheral blood neutrophils and monocytes were oxidase normal. Subjects 1 and 3 retained oxidase-normal neutrophils and monocytes in circulation for more than 5 years after the treatment, although they decreased over the first 7 months to plateau at approximately 1% and 0.03%, respectively. It should be noted that the long-term infection of the liver and lung in subjects 1 and 3, respectively, that had not responded to conventional antibiotic management resolved by 6 months after gene therapy without any change in antibiotic regimen. In addition, subject 1 experienced a marked decrease in the frequency and severity of infection in the 5 years after gene therapy relative to those before the gene therapy provided in this study. No vector-related toxicities in these patients were noted.
A similar trial in Korea used an altered gammaretrovirus vector in which all viral coding sequences were deleted [22] . Two patients were given autologous transduced CD34 + HSCs at doses of 5.4 to 5.6 × 10 6 cells/kg after conditioning with busulfan and fludarabine. The patients achieved a maximum of 11.7% gene-marked cells in the peripheral blood 3 to 4 weeks after gene therapy and a peak of 14.5% oxidase-positive neutrophils according to DHR assay 14 days after gene therapy. However, also in this trial, the percentage of circulating gene-corrected cells rapidly declined, although trace amounts of gene-marked cells were detectable up to 3 years after the infusion. Although integration-site analysis revealed the presence of transgene insertion near proto-oncogenes MDS1 and PRDM16, no adverse hematologic events were observed. Although no clear evidence of clinical improvement was found, patient 2 (who had 
CURRENT GENE-THERAPY TRIALS: 2010 TO PRESENT DAY
After the occurrence of insertional toxicities in gammaretroviral-based gene-therapy trials, development shifted away from gammaretroviral to lentiviral vectors. Unlike gammaretroviruses, lentiviruses can transduce nondividing cells and do not preferentially insert into transcriptionally active genes [10] . Early lentiviral vectors used the human immunodeficiency virus LTR, whereas newer vectors have introduced additional edits to improve safety and ensure physiologic protein expression. Deletion of the U3 segment of the viral LTR has enabled investigators to produce self-inactivating (SIN) vectors that remain static after genome integration. Usage of a promoter from cytomegalovirus or native promoters from the gene of interest or related genes has allowed more physiologic protein expression. Concurrent trials of lentiviral gene therapy for X-CGD that are using an SIN lentiviral vector with a chimeric myeloid promoter created by the fusion of c-Fes and cathepsin G 5'-flanking regulatory regions [23] are underway in Europe and the United States (ClinicalTrials.gov identifiers NCT01855685 and NCT02234934, respectively). The vector also contains a mutated woodchuck hepatitis virus posttranscriptional regulatory element. Included in the US trial (open in Boston, Bethesda, Maryland, and Los Angeles) are patients aged >23 months who lack a matched related or unrelated donor and who have a history of serious infections or inflammatory complications. The trial is using busulfan preconditioning at submyeloablative doses. Although this trial is still underway, the results of studies that used similar vectors for other immunodeficiencies such as SCID and Wiskott Aldrich syndrome have been encouraging [24] [25] [26] . Evidence of clinical benefit from lentivector gene therapy was observed also in clinical trials in which lentivector-transduced CD34 + HSCs were used to treat adrenoleukodystrophy, metachromatic leukodystrophy, and thalassemia [27] [28] [29] [30] . To date, no insertional oncogenesis has occurred in patients who received SIN lentiviral vectors.
TARGETED THERAPY FOR CGD: PRECLINICAL STUDIES
Despite the advances in vector design, gene therapy based on the integration of an additional copy of a wild-type copy of the therapeutic transgene carries unavoidable risks of insertional mutagenesis. Furthermore, the use of heterologous promoters might not provide physiologic levels of gene expression. Advances in gene-editing technology, including zinc-finger nucleases (ZFNs) and the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system, might enable gene addition or repair at the native site or in a genomic "safe harbor. " In preclinical experiments, Malech and collaborators [31] used ZFNs successfully to introduce a normal copy of the gene in the AAVS1 locus in induced pluripotent stem cells from patients with each of the 5 genetic forms of CGD. After in vitro differentiation into neutrophils and macrophages, gene-targeted cells exhibited robust oxidase activity and microbicidal function. A similar approach was used to introduce a normal copy of the CYBB complementary DNA into the AAVS1 locus of CD34 + hematopoietic stem and progenitor cells (HSPCs) derived from patients with X-CGD [32] . In this case, delivery of the ZFN pair via electroporation was followed by delivery of the gp91 phox construct using an adeno-associated virus 6 (AAV6) vector, resulting in a donor template insertion efficiency of up to 38% of HSPCs in vitro, and in up to 10% of HSPCs engrafting up to 20 weeks as human marrow xenografts in the NSG (NOD scid gamma) mouse. A subsequent study used the CRISPR/Cas9 system to repair one of the more common pathogenic CYBB mutations (c.C676T) in CD34 + HPSCs from patients with X-CGD [33] . Electroporation was used to introduce the guide RNA, a 100-bp single-stranded DNA donor template, and Cas9 messenger RNA. The corrected cells exhibited gp91 phox expression in 31% of cells, and after in vitro differentiation, 19.3% of myeloid cells exhibited oxidative activity via DHR assay. Transplantation of these gene-corrected HPSCs into NOD/SCID/γc −/− mice resulted in stable expression of gp91 phox in 14% of peripheral blood at up to 5 months after the transplant.
Although targeted repair of pathogenic mutations seems highly appealing, the level of customization required for this therapy would be limiting. A recent study in an induced pluripotent stem cell model of X-linked CGD attempted to marry the concepts of gene add-back with in-site repair via addition of a CYBB minigene (containing a codon-optimized complementary DNA for gp91 phox ) at the start sites of either exon 1 or exon 2 of the native CYBB locus [34] . The investigators found that insertion of this minigene into exon 1 resulted in no expression of gp91 phox in granulocytes differentiated from the gene-corrected induced pluripotent stem cell clones, whereas insertion into exon 2 resulted in 60% to 100% expression compared to that of normal controls. This result showed the that use of native gene promoters requires an understanding of the necessary regulatory elements that enable gene expression.
Beyond advancements in definitive therapies, the identification of specific pathways that can be targeted to ameliorate the inflammatory and infectious complications of CGD has been an ongoing goal. Inflammatory colitis, retinitis, and granulomatous inflammation of various organs are common manifestations of CGD [2] . Inflammatory complications often require corticosteroid therapy, which can further increase the risk of invasive bacterial and fungal infections in this population. Refractory inflammatory complications are often a driving factor in pursuing definitive therapies. Thus, improved targeted therapies for inflammatory complications could make transplantation unnecessary for a subset of patients with CGD.
Several studies have evaluated potential methods of enhancing residual superoxide production in phagocytes. Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, which are used commonly to treat insulin resistance in type 2 diabetes, have been shown to affect host defense against Candida albicans and various bacteria. Preclinical studies have found that pioglitazone partially restores superoxide production in a murine X-CGD model [35] . This ROS production was shown to be of mitochondrial origin and was largely ablated by treatment with mitochondrial antioxidants. It should be noted that partial ROS restoration was shown to improve killing of Staphylococcus spp and Burkholderia cepacia in vitro and improve bacterial clearance in a murine X-CGD peritonitis model. How enhanced mitochondrial ROS production affects pathogen killing is not yet clear, but evidence that mitochondria can be delivered to phagolysosomes in neutrophils after Toll-like receptor stimulation exists. It has been theorized that PPAR-γ agonists can enhance this form of autophagy and thereby partially restore ROS production in phagolysosomes. Furthermore, PPAR-γ activation has been shown to aid in resolution of sterile inflammation, which suggests that this pathway might have an effect on the inflammatory complications of CGD [36] .
To date, this work has not been reproduced in humans; however, the case of experimental use of pioglitazone in a 5-month-old infant with X-CGD and multiple severe infections has been published [37] . After titration of pioglitazone to 3 mg/kg, a DHR assay showed oxidative activity in 12.9% of granulocytes (versus total absence of oxidative activity before therapy). The medication was tolerated well, and the patient cleared his respiratory infection and underwent subsequent successful HSCT from an human leukocyte antigen-matched sibling. Although these results are encouraging, a prospective clinical trial of pioglitazone in this population is needed to further elucidate its effect on infectious and inflammatory complications of CGD.
Additional studies of the inflammatory cellular prolife in patients with CGD have revealed other abnormalities, including an increased proportion of T-helper 17 (Th-17) CD4 + T cells and increased interleukin 1β (IL-1β), IL-6, and tumor necrosis factor α (TNFα) expression in patient monocytes and macrophages [38, 39] . Inhibition of mTORC1 (mammalian target of rapamycin complex 1) by rapamycin has been shown to induce autophagy, and Gabrion et al [40] hypothesized that rapamycin can reduce levels of inflammatory cytokines in patients with CGD in this manner. The investigators found that culture with rapamycin normalized production of these cytokines in macrophages but not monocytes and reduced IL-17, IL-6, and TNFα production in Th17 cells. Coculture of patient monocytes with rapamycin and anakinra enhanced the reduction of IL-1β.
To date, rapamycin has not been evaluated prospectively in patients with CGD. A report of 2 patients with CGD-associated inflammatory bowel disease treated for 3 months with anakinra showed immediate and persistent improvement of symptoms [38] . However, a follow-up study of 5 patients with severe CGDassociated colitis treated with anakinra found that only 2 of 5 patients experienced significant improvement in their HarveyBradshaw Index scores, but even in these patients the effect was not sustained when treatment of these responders was extended to 1 year [41] . None of the patients presented with infection that required cessation of anakinra. Nonetheless, extreme caution should be taken in considering biological therapies for patients with CGD due to an association between anti-TNF therapy and risk of fatal infections [42] .
CONCLUSIONS
Despite early challenges, advances in gene therapy for patients with CGD are likely to dramatically expand options for definitive therapies. Although current trials are focused on X-CGD, progress in gene-editing technologies and vector development will likely enable future extension of gene therapy to autosomal recessive forms of CGD. In parallel, future trials of targeted therapies to restore defective autophagy and treat inflammatory phenomena might both reduce the risk of undergoing transplantation for patients with CGD and make HSCT or gene therapy unnecessary for some patients. 
